Randomized trial · people
VIP (aviptadil) missed its main goal in critical COVID-19 trial
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In critical COVID-19, IV VIP did not beat placebo on the trial's main outcome, though survival looked better; it says nothing about other uses of VIP.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 196
- Published
- 2022
- Journal
- Crit Care Med
What they tested
The team tested whether aviptadil, a synthetic form of VIP given by IV, could help patients with COVID-19 respiratory failure survive and recover better than placebo.
How the study was done
A randomized, placebo-controlled trial at 10 U.S. hospitals in 196 patients with COVID-19 respiratory failure. Patients were assigned 2:1 to 3 days of IV aviptadil or placebo (a dummy infusion) and followed for 60 days.

What they found
The main goal was being alive and free of respiratory failure at day 60, and aviptadil fell short: its OR (odds ratio, which compares the chance of an outcome on the drug with the chance on placebo) was 1.6, with a 95% CI of 0.86-3.11, so there was no clear difference from placebo. Survival alone at day 60 was better with aviptadil (OR 2.0; 95% CI 1.1-3.9; p = 0.035), and by day 3 the respiratory distress ratio improved and interleukin 6, an inflammation signal, fell (p = 0.02). In subgroups, patients on high-flow nasal oxygen at the start were more likely to reach the main goal (p = 0.039), and those on mechanical ventilation had 10-fold higher odds of survival with the drug (p = 0.031); the team saw no drug-related serious side effects.
What it doesn’t show
The trial failed its main outcome, so the survival and subgroup results are secondary findings that can't settle the question alone. It studied only hospitalized patients with critical COVID-19 who got a short IV course.
The paper
Youssef et al. The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial. Crit Care Med. 2022.
The compound
More studies on VIP
- VIP (aviptadil): discharge at 7.8 vs 10 days in COVID-19Randomized trial · people · 2025
- VIP fragment VIP10-28 boosted, not blocked, skin vessel wideningClinical trial · people · 2005
- VIP: peak flow rose 26 l/min in severe asthma, less than salbutamolClinical trial · people · 1986
- VIP: tear levels rose after laser eye surgery, peaking at 1 weekObservational study · people · 2023
- Every study on VIP
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.